The American Heart Association released a scientific statement detailing a framework for patient selection in the cardiac intensive care unit.
FDA career scientists quietly posted recommendations in several briefing documents advising against easing rules regarding peptides.
Researchers found that finerenone, compared with placebo, decreases sudden death risk in patients with cardio-kidney-metabolic syndrome.